Dun***son
Education
University of Oxford (2011 - 2015)
- Degree: Doctor of Philosophy (PhD)
- Field of Study: Pathology
- Description:
University of Pretoria/Universiteit van Pretoria (2009 - 2011)
- Degree: Master of Science (MSc)
- Field of Study: Microbiology
- Description:
University of Pretoria/Universiteit van Pretoria (2005 - 2009)
- Degree: BSc (Hons)
- Field of Study: Microbiology
- Description:
Skills:
Work Experience:
Director Business Development at Amgen
- Location: Greater Los Angeles, California, United States
- Duration: 2023-07 to Present
- Description:
Senior Manager, Business Development at Amgen
- Location: Thousand Oaks, California, United States
- Duration: 2020-04 to 2023-07
- Description: Deal-making to access next-generation technologies for discovering and developing new medicines. 50+ deals across multiple technology and therapeutic areas. Selected publicly disclosed deals: 𝐀𝐫𝐫𝐚𝐤𝐢𝐬 - 𝐀𝐦𝐠𝐞𝐧: Multi-target collaboration to discover small molecule RNA degraders 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐞 𝐁𝐢𝐨𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 - 𝐀𝐦𝐠𝐞𝐧: Multi-target collaboration to utilize Generate's machine-learning approach for discovery of biologics 𝐄𝐕𝐎𝐐 - 𝐀𝐦𝐠𝐞𝐧: Multi-target collaboration to enable tolerance induction in auto-immune diseases 𝐆𝐑𝐀𝐈𝐋 - 𝐀𝐦𝐠𝐞𝐧: Collaboration to determine patient tumor burden from liquid biopsy derived cfDNA methylation signatures
Director of Product Management at Integral Molecular
- Location: Greater Philadelphia Area
- Duration: 2019-01 to 2020-04
- Description: Lead business development and partnerships for the Membrane Proteome Array - a novel high-throughput platform for novel drug target discovery in therapeutic areas including oncology, auto-immunity and infectious disease. Oversaw restructuring of product and marketing portfolios and alignment with commercial strategy General Manager of a wholly-owned division founded to commercialize certain aspects of the Membrane Proteome Array platform.
Product Manager at Integral Molecular
- Location: Greater Philadelphia Area
- Duration: 2015-11 to 2018-12
- Description: Led the team that developed and commercialized the Membrane Proteome Array (MPA) - an innovative high-throughput screening platform Responsible for commercial strategy of the MPA service business based around off-target screening of biologics to de-risk clinical development. Responsible for overseeing business development and partnerships using the MPA for novel drug target discovery in therapeutic areas including oncology, auto-immunity and infectious disease.
DPhil Student at University of Oxford
- Location: Oxford, United Kingdom
- Duration: 2011-10 to 2015-12
- Description: DPhil in Pathology supervised by Prof. Ervin Fodor at The Sir William Dunn School of Pathology Title: Influenza A Virus: Host Restriction of the Viral Polymerase and a Mechanism for vRNP Nuclear Export Publications: Paterson, D. & Fodor, E. Emerging Roles for the Influenza A Virus Nuclear Export Protein (NEP). PLoS Pathog. 8, e1003019 (2012). Paterson, D., te Velthuis, A. J. W., Vreede, F. T. & Fodor, E. Host restriction of influenza virus polymerase activity by PB2 627E is diminished on short viral templates in a nucleoprotein-independent manner. J. Virol. 88, 339–344 (2014). Resa-Infante, P., Paterson, D. et al. Targeting importin-α7 as a therapeutic approach against pandemic influenza viruses. J. Virol. (2015).
Candidate Intelligence Report
AI-powered analysis from the perspective of a US hiring director — evaluating career continuity, growth trajectory, and role fit.
Career Continuity & Risk Assessment
No significant employment gaps; continuous progression from 2015 through present. A minimal 1-month gap between 2018-12 and 2019-01 is offset by immediate return to employment.
Career remains within biotech/pharma and drug discovery ecosystems (Integral Molecular, Amgen); strong alignment with life sciences deal-making and partnerships.
Demonstrated stable tenure with progressive responsibility: multi-year periods at Integral Molecular and consistent promotions at Amgen, indicating low turnover risk.
Oxford DPhil in Pathology provides a rigorous scientific foundation that complements and supports advanced BD, partnerships, and product strategy in biotech/pharma.
Career Growth Curve
Best-Fit Roles (Top 5)
Vice President, Corporate Development & Alliances95% fit
Proven track record of leading high-value deals and strategic partnerships across multiple platforms, with current Amgen BD leadership experience.
Senior Vice President, Strategic Partnerships92% fit
Extensive deal-making history (50+ deals) and cross-therapy/technology collaboration experience; aligns with global partnership strategy at scale.
Head of Strategic Partnerships90% fit
Strong partnership management and product-BD integration background; suitable for leading a partner ecosystem in a growth-stage or established biotech.
Director/Head of Corporate Development86% fit
Direct experience in deal structuring and portfolio strategy; natural progression for a leader aiming to run BD/CORP Dev for a mid-to-large biotech.
Global Partnerships Director83% fit
Experience with multinational collaborators and a global deal lens; suitable for roles focusing on global BD and alliance networks.
Related Sourcing Channels
Groups and Events where you can find more candidates with similar skills and background.
Experience AI Recruiter
$0 to start. Don't let your competitors get the AI advantage first.
Join over 10,000 companies using AI-driven recruitment solutions to automate your hiring process and save 80% in time costs.
24/7 automated operation
AI-powered candidate screening
Recruitment without geographical or time zone limitations
Personalized intelligent communication
Automated assessment of candidate engagement
Intelligently mimics and replicates your recruitment style
4-month money-back guarantee
Ensures LinkedIn account security
©Strategybrain Technology Ltd.
info@strategybrain.ca